Kalled Musallam: A Comprehensive Review of Thalassemia
Kalled Musallam, Group Chief Research Officer at Burjeel Holdings and Deputy CEO and Chief of Cellular and Gene Therapy and Hematology at Burjeel Cancer Institute, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Nature Reviews Disease Primers, adding:
“Pleased to share our new comprehensive review on thalassemia published today in Nature Reviews Disease Primers, one of the leading journals from the Nature portfolio (impact factor 80), which will hopefully provide thalassemia with greater visibility across the broader scientific and medical community.”
Title: Thalassaemia
Authors: Frédéric B. Piel, Mariane de Montalembert, Reena Das, Kevin H. M. Kuo, Ali T. Taher, Khaled M. Musallam, Marsha Treadwell, Suthat Fucharoen, Michael Angastiniotis, Douglas Higgs, Elliott Vichinsky, Maria Domenica Cappellini, Lucia De Franceschi
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 15, 2026, 02:59Caterina Casari: Curious about How Gene Editing is Revolutionizing Our Field?
-
Sep 15, 2026, 02:53Alejandro González Veliz: Can Lifestyle Changes Actually Reverse Atherosclerosis?
-
Sep 15, 2026, 02:08Eugenia Gianos: ACC CVPrevention Council’s New Statin Resources
-
Sep 15, 2026, 01:58Shinya Goto: Country Specific Randomized Trial Show the Merit of DOAC in Intermediate Risk of A
-
Sep 15, 2026, 01:37Lesley Van Wyk: Exploring Sickle Cell Disease – The HbS Story
-
Sep 15, 2026, 01:31Luca Seffin: To the Science, the People, and the Journey – Thank You SR-Tiget
-
Sep 14, 2026, 23:49Heghine Khachatryan: New evidance – Antiphospholipid Antibodies and Ischemic Stroke
-
Sep 14, 2026, 23:42Eman M. Elsabbagh: Successful HCT Does Not End at Engraftment
-
Sep 14, 2026, 23:31Antonis Kattamis: Proud to Be Part of this Endeavour and Senior Author of the Pivotal Trial